333
Participants
Start Date
July 13, 2019
Primary Completion Date
July 13, 2020
Study Completion Date
July 13, 2020
Mexidol
125 mg tablets
Placebo
Placebo tablets
Mexidol + Placebo
Combination of Mexidol and Placebo
"Federal State Autonomous Educational Institution of Higher Education Russian National Research Medical University named after N.I. Pirogov Ministry of Health of the Russian Federation", Moscow
"State Budgetary Healthcare Institution of the City of Moscow Scientific and Practical Center for Child Psychoneurology of the Moscow Department of Healthcare", Moscow
"Federal State Budgetary Educational Institution of Higher Education Tver State Medical University Ministry of Health of the Russian Federation", Tver'
"Limited Liability Company Medical Technologies", Saint Petersburg
"State Budgetary Healthcare Institution Specialized Clinical Psychiatric Hospital №1 of the Ministry of Health of the Krasnodar Territory", Krasnodar
"Limited Liability Company Center for Professional Therapy", Krasnodar
"Limited Liability Company DNA Research Center", Saratov
"Federal State Budgetary Educational Institution of Higher Education Kazan State Medical University Ministry of Health of the Russian Federation", Kazan'
"State Healthcare Institution Central Clinical Medical-Sanitary Unit named after Honored Doctor of Russia V.A. Egorov", Ulyanovsk
"State Budgetary Healthcare Institution Orenburg Regional Clinical Psychiatric Hospital №1", Orenburg
"Limited Liability Company NizhMedClinic", Nizhny Novgorod
"State Autonomous Healthcare Institution of the Sverdlovsk Region Multispecialty Clinical Medical Center 'Bonum'", Yekaterinburg
"Limited Liability Company European Medical Center 'UGMK-Health'", Yekaterinburg
"Federal State Budgetary Educational Institution of Higher Education Tyumen State Medical University Ministry of Health of the Russian Federation", Tyumen
Lead Sponsor
Pharmasoft
INDUSTRY